Ewopharma and BioGaia extend their long-standing partnership
BioGaia AB (NASDAQ: BIOG) and Ewopharma AG have renewed their long-standing distribution partnership, reinforcing the co…
Ewopharma AG
Ewopharma and Dr. Falk Pharma renew their long-standing partnership - a commitment built to last
Ewopharma AG and Dr. Falk Pharma GmbH are extending their distribution partnership of more than 27 years – for many more…
Sugemalimab Receives I, A Recommendation in ESMO Guideline for Consolidation Therapy in Patients with Stage III NSCLC
Ewopharma is pleased to report that sugemalimab, licensed from partner CStone Pharmaceuticals, has received a I, A recom…
Sugemalimab Achieves New Regulatory Milestone: European Commission Approves Stage Ⅲ NSCLC Indication
Ewopharma is pleased to report an important new regulatory milestone for sugemalimab licensed from Chinese partner CSton…
Ewopharma AG Announces Exclusive Distribution Agreement for Cardiovascular Solutions in Bulgaria
Effective June 1, 2024, Ewopharma AG has the exclusive licence to distribute Translumina’s drug-eluting stents (DES) and…
AllergyCare AG Becomes Part Of Ewopharma Group
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to ann…
Ewopharma and CStone enter into a Strategic Partnership for Sugemalimab in Central Eastern Europe and Switzerland
Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CS…
Neomed s.r.o. becomes part of Ewopharma Group
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to ann…
Ewopharma and Eisai Announce Commercial Partnership in Central Eastern Europe for Lenvima® (lenvatinib)
Ewopharma, a pharmaceutical marketing company and Eisai Europe Ltd., a leading global research and development-based pha…
Otsuka și Ewopharma AG se alătură luptei împotriva tuberculozei, în România, prin lansarea medicamentului orfan dezvoltat de Otsuka - Deltyba® (delamanid) pentru tuberculoza plurirezistentă la medicamente
Tuberculoza (TBC) este principala cauză de deces provocat de o boală infecțioasă, la nivel global.[1] Otsuka Pharmaceuti…
